Deleyrolle Loic P, Rohaus Mark R, Fortin Jeff M, Reynolds Brent A, Azari Hassan
Department of Neurosurgery, The University of Florida, USA.
J Vis Exp. 2012 Apr 29(62):3918. doi: 10.3791/3918.
Tumor heterogeneity represents a fundamental feature supporting tumor robustness and presents a central obstacle to the development of therapeutic strategies(1). To overcome the issue of tumor heterogeneity, it is essential to develop assays and tools enabling phenotypic, (epi)genetic and functional identification and characterization of tumor subpopulations that drive specific disease pathologies and represent clinically relevant targets. It is now well established that tumors exhibit distinct sub-fractions of cells with different frequencies of cell division, and that the functional criteria of being slow cycling is positively associated with tumor formation ability in several cancers including those of the brain, breast, skin and pancreas as well as leukemia(2-8). The fluorescent dye carboxyfluorescein succinimidyl ester (CFSE) has been used for tracking the division frequency of cells in vitro and in vivo in blood-borne tumors and solid tumors such as glioblastoma(2,7,8). The cell-permeant non-fluorescent pro-drug of CFSE is converted by intracellular esterases into a fluorescent compound, which is retained within cells by covalently binding to proteins through reaction of its succinimidyl moiety with intracellular amine groups to form stable amide bonds(9). The fluorescent dye is equally distributed between daughter cells upon divisions, leading to the halving of the fluorescence intensity with every cell division. This enables tracking of cell cycle frequency up to eight to ten rounds of division(10). CFSE retention capacity was used with brain tumor cells to identify and isolate a slow cycling subpopulation (top 5% dye-retaining cells) demonstrated to be enriched in cancer stem cell activity(2). This protocol describes the technique of staining cells with CFSE and the isolation of individual populations within a culture of human glioblastoma (GBM)-derived cells possessing differing division rates using flow cytometry(2). The technique has served to identify and isolate a brain tumor slow-cycling population of cells by virtue of their ability to retain the CFSE labeling.
肿瘤异质性是支持肿瘤稳健性的一个基本特征,也是治疗策略开发的核心障碍(1)。为克服肿瘤异质性问题,开发能够对驱动特定疾病病理且代表临床相关靶点的肿瘤亚群进行表型、(表观)遗传和功能鉴定及表征的检测方法和工具至关重要。现已明确,肿瘤表现出具有不同细胞分裂频率的不同细胞亚群,并且在包括脑、乳腺、皮肤、胰腺肿瘤以及白血病在内的多种癌症中,慢周期功能标准与肿瘤形成能力呈正相关(2-8)。荧光染料羧基荧光素琥珀酰亚胺酯(CFSE)已用于在体外和体内追踪血行性肿瘤和实体瘤(如胶质母细胞瘤)中细胞的分裂频率(2,7,8)。CFSE的细胞渗透性非荧光前药被细胞内酯酶转化为荧光化合物,该化合物通过其琥珀酰亚胺部分与细胞内胺基反应形成稳定酰胺键,从而与蛋白质共价结合而保留在细胞内(9)。荧光染料在细胞分裂时均匀分布于子代细胞之间,导致每次细胞分裂时荧光强度减半。这使得能够追踪多达八至十轮的细胞周期频率(10)。CFSE保留能力被用于脑肿瘤细胞,以鉴定和分离一个慢周期亚群(前5%保留染料的细胞),该亚群被证明富含癌症干细胞活性(2)。本方案描述了用CFSE对细胞进行染色的技术,以及使用流式细胞术从人胶质母细胞瘤(GBM)衍生细胞培养物中分离具有不同分裂速率的单个群体的方法(2)。该技术凭借细胞保留CFSE标记的能力,已用于鉴定和分离脑肿瘤慢周期细胞群体。